The JV will formulate Leuprolide in a proprietary controlled-release drug delivery platform technology, developed by Foresee. Under the JV, ScinoPharm will act as the exclusive provider of Leuprolide
Under the deal, Afraxis will earn around $187.5m in total as upfront, research, development and commercialization milestone payments. Afraxis president and CEO and Avalon Ventures managing partner Jay
The completion of cGMP manufacturing, which resulted in a high yield batch of DM-199, allows the company to use DM-199 compound in its upcoming clinical trials. The company
The partnership will focus on developing and validating the diagnostic EP-AD assay for use as both a biomarker, useful in AD related clinical studies, and an FDA-approved AD
The regulatory agency approved Kynamro 200mg subcutaneous injection per week as an added therapy to lipid-lowering medications and diet in HoFH patients. Kynamro will reduce low density lipoprotein-cholesterol
The renewal was followed by a cGMP inspection conducted by Spanish health authorities at the manufacturing facility. TiGenix CTO Wilfried Dalemans said the Madrid GMP facility manufactures high-quality,
Lonza completed validation of viral-induced cell processing GMP suites and completed the tech transfer process. Lonza viral-based therapeutics head David Enloe said, "We are pleased to have been
Baxter said, in conjunction with Inspiration’s ongoing bankruptcy proceedings, it will also acquire certain other OBI-1 related assets including manufacturing operations from Ipsen Pharma. Recombinant porcine factor VIII
The clinical development program includes Phase II studies evaluating IDX719, simeprevir (TMC435) and TMC647055 for the treatment of HCV after an initial drug-drug interaction study, expected to commence
Champion said each 3.6g packet of Invigorate is packed with 250mg of Sustamine, which combines amino acids including L-Alanine and L-Glutamine. During a study at the University of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.